Harmony Biosciences Holdings (Harmony Biosciences Holdings) Net Margin % : 15.80% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Harmony Biosciences Holdings's Net Income for the three months ended in Dec. 2023 was $26.6 Mil. Harmony Biosciences Holdings's Revenue for the three months ended in Dec. 2023 was $168.4 Mil. Therefore, Harmony Biosciences Holdings's net margin for the quarter that ended in Dec. 2023 was 15.80%.

The historical rank and industry rank for Harmony Biosciences Holdings's Net Margin % or its related term are showing as below:

HRMY' s Net Margin % Range Over the Past 10 Years
Min: -2535.06 Med: 11.33 Max: 41.44
Current: 22.14

HRMY's Net Margin % is ranked better than
90.48% of 1029 companies
in the Biotechnology industry
Industry Median: -162.58 vs HRMY: 22.14

Harmony Biosciences Holdings Net Margin % Historical Data

The historical data trend for Harmony Biosciences Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings Net Margin % Chart

Harmony Biosciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-2,535.06

-23.13

11.33

41.44

22.14

Harmony Biosciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															37.81	24.75	25.56	24.00	15.80

Competitive Comparison of Harmony Biosciences Holdings's Net Margin %

For the Biotechnology subindustry, Harmony Biosciences Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harmony Biosciences Holdings's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Net Margin % falls into.

Harmony Biosciences Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Harmony Biosciences Holdings's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	128.853	/	582.022
	=	22.14 %

Harmony Biosciences Holdings's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	26.607	/	168.412
	=	15.80 %

Harmony Biosciences Holdings (NAS:HRMY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Harmony Biosciences Holdings Net Margin % Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Harmony Biosciences Holdings (Harmony Biosciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462

Website

https://www.harmonybiosciences.com

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Executives

Peter Anastasiou	director	C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andreas Wicki	director	C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Andrew Serafin	officer: Chief Business Officer	630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno	officer: Chief Medical Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Jeffrey Dierks	officer: Chief Commercial Officer	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
John C Jacobs	director, officer: President, CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Sandip Kapadia	officer: Chief Financial Officer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
R. Mark Graf	director	C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Eric L Motley	director	1516 33RD STREET NW, WASHINGTON DC 20007
Valor Equity Partners Iv-a L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Valor Equity Partners Iv-b L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Marshman Fund Trust Ii	10 percent owner	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Equity Capital Iv Llc	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611